- 300 mg - Tenofovir disoproxil fumarate;
- 245 mg - Equivalent to tenofovir disoproxil;
- 200 mg - Emtricitabine;
Without a Prescription
Tenofovir is prescribed in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.
The following points should be considered when initiating therapy with Tenofovir for the treatment of HIV-1 infection.
It is not recommended that Tenofovir be used as a component of a triple nucleoside regimen.
Tenofovir should not be coadministered with lamivudine+tenofovir DF+Efavirenz, emtricitabine,tenofovir DF or lamivudine-containing products [ see WARNINGS AND PRECAUTIONS ] .
In treatment experienced patients, the use of Tenofovir should be guided by laboratory testing and treatment history
Tenofovir dosage is one tablet once daily taken orally with or without food.
Dose adjustment for renal impairment:
Significantly increased drug exposures occurred when emtricitabine or tenofovir DF were administered to patients with moderate to
severe renal impairment. Therefore, the dosing interval of Tenofovir should be adjusted in patients with baseline creatinine
clearance of 30-49 mL/min using the recommendations in Table 2. The safety and effectiveness of these dosing interval
adjustment recommendations have not been clinically evaluated; therefore, clinical response to treatment and renal function
should be closely monitored in these patients.
No dose adjustment is necessary for patients with mild renal impairment (creatinine clearance of 50-80 mL/min). Routine
monitoring of calculated creatinine clearance and serum phosphorus should be performed in patients with mild renal impairment.
Container of 30 tablets.